Duration of Vi antibodies in participants vaccinated with Typhim Vi (Typhoid Vi polysaccharide vaccine) in an area not endemic for typhoid fever

被引：17

作者：

Froeschle, James E. ^{[1
]}

Decker, Michael D. ^{[1
,2
]}

机构：

[1] Sanofi Pasteur, Sci & Med Affairs, Swiftwater, PA 18370 USA

[2] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA

来源：

VACCINE | 2010年 / 28卷 / 06期

关键词：

Vaccines; Vi polysaccharide vaccine; Typhoid; Bacterial Polysaccharides; CAPSULAR POLYSACCHARIDE; SALMONELLA-TYPHI; IMMUNIZATION; SAFETY; IMMUNOGENICITY; PREVENTION;

D O I：

10.1016/j.vaccine.2009.11.051

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

After a single injection of Typhim Vi (R) (typhoid Vi polysaccharide vaccine), serum antibody concentrations were monitored for 3 years in 37 adults who resided where typhoid fever was not endemic. Anti-Vi antibody concentrations declined progressively during the study, to levels that support the current US recommendation for revaccination every 2 years. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：1451 / 1453

页数：3

共 15 条

[11]

Overbosch D, 2005, J TRAVEL MED, V12, P319, DOI 10.2310/7060.2005.12604

[12] Typhoid fever [J].

Parry, CM ;

Hien, TT ;

Dougan, G ;

White, NJ ;

Farrar, JJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (22) :1770-1782

[13] A NEW TYPHOID VACCINE COMPOSED OF THE VI CAPSULAR POLYSACCHARIDE [J].

PLOTKIN, SA ;

BOUVERETLECAM, N .

ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (21) :2293-2299

[14] Typhoid fever in travelers: Who should be targeted for prevention? [J].

Steinberg, EB ;

Bishop, R ;

Haber, P ;

Dempsey, AF ;

Hoekstra, RM ;

Nelson, JM ;

Ackers, M ;

Calugar, A ;

Mintz, ED .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (02) :186-191

[15]

2005, TYPHIM VI TYPHOID VI

← 1 2 →